Gestational Diabetes MellitusPhase 4DECIDENCT06445946
DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes
A Phase 4 study testing Metformin and Insulin in people with Gestational Diabetes Mellitus and Pregnancy, High Risk, run by Ohio State University at 26 sites in United States.
Trial summary
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin. Read more about this study
- Who is it for?
- Ages 18 years and older, women only
- Conditions the study is for
- Gestational Diabetes Mellitus, Pregnancy, High Risk
- What is being tested?
- Metformin and Insulin
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,572 participants
- Where
- 26 sitesUnited States
- Study dates
- 1 Aug 2024to Dec 2030
- Phase
- Phase 4
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Singleton gestation. Twin reduction to singleton, either spontaneously or therapeutically, is eligible if it occurred before 14 weeks gestational age.
- Age 18 years or older
- Gestational age at randomization between 20 0/7 - 33 6/7 weeks based on project gestational age.
- GDM diagnosis less than or equal to 33 6/7 weeks based on project gestational age.
- Requires medication for glucose control defined as ≥ 30% elevated glucose values (either fasting or postprandial or both) prior to randomization per determination of the provider or documented in the medical record.
- Patient willingness and ability to attend 2-year follow-up visit.
Who cannot join
- Renal disease (serum creatinine >1.3 mg/dL) due to the potential impact of metformin on renal function.
- Major structural malformation of the fetus.
- Known fetal aneuploidy based on invasive testing or positive for aneuploidy on cell-free fetal DNA screening.
- Contraindication to metformin or insulin, including: history of lactic acidosis, intractable nausea and vomiting, prior documented allergy and/or anaphylaxis.
- For individuals with GDM diagnosed <20 0/7 weeks, documented A1c ≥>6.5% within prior 6 months.
- Pregestational diabetes documented in the medical record or prior A1c>= 6.5%
Show all 11Show fewer
- Fasting hyperglycemia >115 mg/dl for ≥ 50% of fasting glucose values in the past week (due to the high risk of metformin failure with fasting hyperglycemia).
- Enrolled in a trial that influences primary study outcomes (composite neonatal outcome at delivery or childhood body mass index at 2 years).
- Prenatal care or delivery planned at a location where access to the complete electronic medical record will not be available to research staff.
- Language barrier (appropriate translation resources unavailable at the site)
- Participation in this trial in a previous pregnancy. Patients who were screened in a previous pregnancy, but not randomized, may be included.
Trial locations and contacts
26 sites in 1 country. Contact the study team or a site near you to ask about taking part.
26 sites in 1 country
United States26 sites, 23 recruiting
- Recruiting
University of New Mexico
Albuquerque, New Mexico, 87131
Vivek Katukuri, MD, vkatukuri@salud.unm.edu
Karen Taylor, kataylor@salud.unm.edu
- Recruiting
University of Texas Austin
Austin, Texas, 78705
Lorie Harper, MD, lorie.harper@austin.utexas.edu
Mickey Roberts, Mickey.roberts@austin.utexas.edu
- Recruiting
Austin Maternal Fetal Medicine
Austin, Texas, 78758
Mollie McDonnold, MD, 512-821-2540
Heather Azarmehr, MSN, RN, 737-415-6210, Heather.Azarmehr@stdavids.com
- Recruiting
Tufts University
Boston, Massachusetts, 02111
Erika Werner, MD, erika.werner@tuftsmedicine.org
Beth Marsh, Beth.Marsh@tuftsmedicine.org
- Recruiting
Massachusetts General Hospital
Boston, Massachusetts, 02114
Lydia Shook, MD, lshook@mgh.harvard.edu
Nancy Kingori, nkingori@mgb.org
- Terminated
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215
- Withdrawn
University of North Caroline
Chapel Hill, North Carolina, 27599
- Recruiting
The Ohio State University Wexner Medical Center OB/GYN Maternal and Fetal Medicine
Columbus, Ohio, 43210
Kartik Venkatesh, MD, PhD, 614-293-2222, Kartik.Venkatesh@osumc.edu
Kartik Venkatesh, MD, PhD
- Recruiting
Premier Health - Miami Valley Hospital
Dayton, Ohio, 45409
Samantha Wiegand, MD, slwiegand@premierhealth.com
Emily Reynolds, ESReynolds@premierhealth.com
- Recruiting
University of South Carolina Greenville
Greenville, South Carolina, 29605
Kacey Eichelberger, MD, kacey.eichelberger@prismahealth.org
Patti Parker, patti.parker@prismahealth.org
- Recruiting
University of Texas Health Science Center
Houston, Texas, 77030
Hector Mendez-Figueroa, MD, hector.mendezfigueroa@uth.tmc.edu
Laura Nixon, Laura.Nixon@uth.tmc.edu
- Not yet recruiting
Kettering Health
Kettering, Ohio, 45429
Hind Moussa, MD, 937-610-3220, Hind.Moussa@ketteringhealth.org
Michelle Pershing, Michelle.Pershing@ketteringhealth.org
- Recruiting
Cedars Sinai Medical Center
Los Angeles, California, 90048
Tania Esakoff, MD, Tania.esakoff@cshs.org
Marla Sharp, Marla.Sharp@cshs.org
- Recruiting
Medical College of Wisconsin
Milwaukee, Wisconsin, 53226
Anna Palatnik, MD, 414-955-2781, apalatnik@mcw.edu
Alyssa Hernandez, DO, 414-955-2781, alyhernandez@mcw.edu
- Recruiting
Yale School of Medicine
New Haven, Connecticut, 06520
Tulin Ozcan, MD, 203-785-5855, tulin.ozcan@yale.edu
Lauren Perley, MA, lauren.perley@yale.edu
- Recruiting
Columbia University Irving Medical Center
New York, New York, 10032
Noelia Zork, MD, nmz2110@cumc.columbia.edu
Joseph Celentano, jmc2476@cumc.columbia.edu
- Withdrawn
Christiana Care
Newark, Delaware, 19718
- Recruiting
Eastern Virginia Medical School - Old Dominion University
Norfolk, Virginia, 23501
Malgorzata Mlynarczyk, MD, mlynarm@evms.edu
Cheryl Sparrer, SparreCD@evms.edu
- Recruiting
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Celeste Durnwald, MD, 215-615-3817, Celeste.Durnwald@pennmedicine.upenn.edu
Elizabeth Norton, MPH, MBE, 215-615-3817, Elizabeth.Norton@pennmedicine.upenn.edu
- Recruiting
University of Pittsburgh
Pittsburgh, Pennsylvania, 15213
Maisa Feghali, MD, feghalim@mwri.magee.edu
John Collins, collinsjn@mwri.magee.edu
- Recruiting
Brown University
Providence, Rhode Island, 02912
Martha Kole-White, MD, mkolewhite@kentri.org
Kelsey Inglesby, KInglesby@Wihri.org
- Recruiting
University of California San Francisco
San Francisco, California, 94143
Nasim Sobhani, MD, Nasim.sobhani@ucsf.edu
Magie Fong, magie.fong@ucsf.edu
- Recruiting
Washington University in St. Louis
St Louis, Missouri, 63130
Megan Lawlor, MD, lawlor@wustl.edu
Emily Diveley, BSN, RN, 314-362-4685, diveley@wustl.edu
- Recruiting
University of South Florida
Tampa, Florida, 33620
Anjali Kaimal Kaimal, MD, akaimal@usf.edu
Maha Jumaily, mahaaljumaily@usf.edu
- Recruiting
University of Alabama
Tuscaloosa, Alabama, 35487
Ashley Battarbee, MD, anbattarbee@uabmc.edu
Michael Jordan, mejordan@uabmc.edu
- Recruiting
Wake Forest University
Winston-Salem, North Carolina, 27106
David Stamilio, MD, dstamili@wakehealth.edu
Christina Tulbert, ctulbert@wakehealth.edu
About this study
Official title: DECIDE: A Comparative Effectiveness Trial of Oral Metformin Versus Injectable Insulin for the Treatment of Gestational Diabetes
This is a non-inferiority patient-centered and pragmatic comparative-effectiveness pregnancy randomized controlled trial (RCT) with postpartum maternal and child follow-up through 2 years of 1,572 individuals with gestational diabetes mellitus (GDM) randomized to oral metformin versus injectable insulin.
This study will determine if metformin is not inferior to insulin in reducing adverse pregnancy outcomes, is comparably safe for exposed individuals and children, and if patient-reported factors, including facilitators of and barriers to use, differ between metformin and insulin. A total of 1,572 pregnant individuals with GDM who need pharmacotherapy will be recruited at 20 U.S. sites using consistent treatment criteria to metformin versus insulin. Participants and their children will be followed through delivery to two years postpartum.
Read the detailed description
Gestational diabetes mellitus (GDM) is one of the most common medical complications of pregnancy. Glycemic control decreases the risk of adverse pregnancy outcomes for the pregnant individual with GDM and the infant exposed in utero (1). One in four individuals with GDM will require pharmacotherapy to achieve glycemic control. Insulin has been the mainstay of pharmacotherapy. Metformin is an alternative option increasingly used in clinical practice (2). Both insulin and metformin reduce the risk of adverse pregnancy outcomes, but comparative effectiveness data from a well-characterized, adequately powered, and diverse U.S. population remain lacking (3). Because metformin crosses the placenta, long-term safety data, in particular the risk of childhood obesity, from exposed children are also needed. In addition, the patient-reported experiences of individuals with GDM requiring pharmacotherapy remains to be characterized, including barriers for and facilitators of metformin versus insulin use.
In a two-arm open-label, pragmatic comparative effectiveness randomized controlled trial (RCT), the DECIDE Study will examine whether metformin is not inferior to insulin in reducing adverse pregnancy outcomes and is comparably safe for exposed mothers and children, and whether patient-reported factors, including facilitators of and barriers to use, differ between metformin versus insulin use. The DECIDE Study Consortium will recruit and retain 1,572 pregnant individuals with GDM who need pharmacotherapy at 20 U.S. sites to metformin versus insulin and follow them and their children through delivery and then to 2-years
Primary aim:
To evaluate whether outcomes in pregnant individuals randomized to metformin are not inferior to those in pregnant individuals randomized to insulin for the composite adverse neonatal outcome defined as large-for-gestational-age birthweight (LGA), hypoglycemia, hyperbilirubinemia, or death.
Secondary aims:
- To evaluate whether mean child body mass index (BMI) at 2 years of age is higher in the offspring of pregnant individuals randomized to metformin.
- To conduct a qualitative or mixed-methods analyses on a subgroup of participants to understand facilitators and barriers associated with metformin versus insulin use and heterogeneity of treatment effects (HTE) to facilitate evidence-based pharmacotherapy.
- To evaluate whether pregnant individuals randomized to metformin have equivalent maternal (hypertensive disorder of pregnancy, gestational weight gain, mode of delivery, and obstetric anal sphincter injuries) and neonatal (preterm birth, mechanical ventilation, NICU admission, oxygen support, and respiratory distress syndrome) outcomes.
- To evaluate whether pregnant individuals randomized to metformin have equivalent maternal (obesity, anthropometry, adiposity, diabetes, hypertension, cholesterol, and metabolic profile) and child (obesity, anthropometry, and adiposity) outcomes at 2-years postpartum.
- To evaluate whether pregnant individuals randomized to metformin have equivalent patient-reported outcomes (PROs), as measured at 6 weeks postpartum and at 2 years postpartum.
- Keywords
- Insulin, Pregnancy, Glycemic control, Metformin, Gestational diabetes, Diabetes, Adverse pregnancy outcomes
- Medical subject headings
- Diabetes, Gestational, Insulin Resistance, Diabetes Mellitus
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MetforminDrug
Individuals randomized to this arm will receive oral metformin tablets for their Gestational diabetes mellitus treatment.
InsulinDrug
Individuals randomized to this arm will receive injectable insulin for their Gestational diabetes mellitus treatment.
| Study group | Role | What they receive |
|---|---|---|
| Metformin | Experimental | Metformin as either immediate- or extended-release formulations can be utilized, and titrated to a maximum daily dose of 2,500 mg. Participants receiving metformin will have insulin added only if they have not achieved euglycemia for at least 30% of glucose values after generally receiving the maximum daily dose of metformin of 2,500 mg, or in select situations in the setting of participant intolerance due to mild gastrointestinal symptoms. Participants will be asked to continue taking metformin after treatment supplementation with insulin. Receives: Drug: Metformin |
| Insulin | Experimental | Insulin will be initiated utilizing clinical standards using trimester-specific weight-based dosing criteria, including both basal and prandial insulins for up to a total of 4 daily injections. Consistent with clinical practice, some people may be managed with a single dose of intermediate- or long-acting insulin at night to treat isolated fasting hyperglycemia, while others may require additional treatment of postprandial hyperglycemia with shorter-acting insulin. The sites' insulin formularies include rapid- (Novolog and Humalog), intermediate- (Humulin N, Novolin N, and NPH), and long-acting insulins (Detemir and Lantus). Receives: Drug: Insulin |
What is being measured
The primary outcome is the main question the study is designed to answer.
A neonatal composite adverse outcome of large-for-gestational-age (LGA) birthweight, hypoglycemia, hyperbilirubinemia, and/or death.
LGA will be defined as a birthweight ≥90th%tile for gestational age based on a US birth certificate reference adjusted for parity and/or fetal sex. Neonatal hypoglycemia will be defined as a blood glucose <35 mg/dL or treatment <24 hours after birth with either IV, PO, or gel glucose therapy. Neonatal hyperbilirubinemia will be defined as treated with phototherapy or exchange transfusion in the first postnatal week and either treatment in the first postnatal week or kernicterus. Fetal or neonatal death can be due to any indication between randomization to hospital discharge or 30 days postnatal if still hospitalized (excluding voluntary pregnancy termination).
Measured: LGA at birth. Hypoglycemia <24 hours after birth. Hyperbilirubinemia within the first week after birth. Death between randomization to hospital discharge or 30 days postnatal.
Child body mass index (BMI) at 2 years of age
Child BMI measured in kg/m2 as a continuous measure standardized using U.S. CDC reference adjusted for child sex
Measured: 2 years of age.
Secondary outcomes (26)
Hypertensive disorder of pregnancy, HDP (maternal)
HDP will include either gestational hypertension or preeclampsia. Gestational hypertension will be defined as: systolic blood pressure of 140 mm Hg or more or diastolic blood pressure of 90 mm Hg or more on two occasions at least 4 hours apart after 20 weeks of gestation in a woman with a previously normal blood pressure. Preeclampsia will be defined as: above blood pressure criteria AND proteinuria (300 mg or more per 24 hour urine collection, protein/creatinine ratio of 0.3 mg/dL or more, or dipstick reading of 2+) OR thrombocytopenia (platelet count less than 100 109/L), renal insufficiency (serum creatinine greater than 1.1 mg/dL or a doubling of the serum creatinine concentration in the absence of other renal disease), impaired liver function (elevated blood concentrations of liver transaminases to twice normal concentration), pulmonary edema, new-onset headache or visual symptoms not attributed to other diagnoses.
Measured: Randomization to delivery
Gestational weight gain (maternal)
Gestational weight gain between weight at first prenatal visit and weight at delivery based on z-score and defined as excess versus within Institute of Medicine (IOM) recommendations based on first pregnancy BMI.
Measured: Initiation of prenatal care to delivery
Mode of delivery (maternal)
Cesarean delivery or vaginal delivery
Measured: At birth
Obstetric perineal/anal sphincter injuries (maternal)
First degree: Injury to perineal skin only; Second degree: Injury to perineum involving perineal muscles but not involving anal sphincter; Third degree: Injury to perineum involving anal sphincter complex, including 3a: Less than 50% of external anal sphincter thickness torn; 3b: More than 50% external anal sphincter thickness torn; and 3c: Both external anal sphincter and internal anal sphincter torn; and Fourth degree: Injury to perineum involving anal sphincter complex (external anal sphincter and internal anal sphincter) and anal epithelium.
Measured: At birth
Preterm birth (child)
Preterm birth <37 weeks and <34 weeks based on project gestational age
Measured: At birth
Requiring mechanical ventilation (child)
Intubation, continuous positive airway pressure (CPAP) or high-flow nasal cannula (HFNC) for ventilation or cardiopulmonary resuscitation within first 72 hours of birth
Measured: <72 hours after birth
NICU admission (child)
Admitted to NICU or intermediate nursery ≥72 hours, any indication
Measured: Birth to delivery discharge.
Oxygen support (child)
Requiring oxygen support
Measured: <72 hours after birth
Respiratory distress syndrome (child)
Signs of respiratory distress with oxygen requirement and confirmed by chest x-ray.
Measured: Anytime during the first 72 hours after birth
Body mass index (BMI) (maternal)
Continuous measure, using standardized protocol as kg/m2.
Measured: 2-year follow-up
Obesity overall and by class (maternal)
BMI per the following classifications: Normal or underweight: < 25 kg/m2; Overweight: 25 to < 30 kg/m2; Class 1: 30 to < 35 kg/m2; Class 2: 35 to < 40 kg/m2; and Class 3: 40 kg/m2 or greater.
Measured: 2-year follow-up
Anthropometry (maternal)
Waist circumference, continuous measures in cm
Measured: 2-year follow-up
Anthropometry (maternal)
Hip circumference, continuous measures in cm
Measured: 2-year follow-up
Anthropometry (maternal)
Waist - to - hip ratio, continuous measure
Measured: 2-year follow-up
Adiposity (maternal)
Triceps, subscapular, suprailiac skinfolds, continuous measures in cm
Measured: 2 year follow-up
Type 2 diabetes (maternal)
A1c > 6.5% OR fasting plasma glucose > 126 mg/dL OR OGTT > 200 mg/dL OR prior diagnosis per patient report
Measured: 2-year follow-up.
Prediabetes (maternal)
A1c 5.7% to 6.4% OR fasting plasma glucose 100 mg/dl to 125 mg/dL OR OGTT 140 to 199 mg/dL
Measured: 2-year follow-up.
Hypertension (maternal)
Per American Heart Association criteria as below and/or antihypertensive medication or prior diagnosis per patient report, and defined as: Elevated: Systolic between 120-129 and diastolic less than 80 mm Hg; Stage 1: Systolic between 130-139 or diastolic between 80-89 mm Hg; and Stage 2: Systolic at least 140 or diastolic at least 90 mm Hg.
Measured: 2-year follow-up.
Cholesterol (maternal)
Fasting state, defined as a continuous measure and dichotomous at the following thresholds for each component: Total cholesterol: > 200 mg/dL; LDL cholesterol: > mg/dL; HDL cholesterol: < 40 mg/dL; Triglycerides: > 200 mg/dL.
Measured: 2-year follow-up.
Hemoglobin A1c (maternal)
Continuous measure, percentage.
Measured: 2-year follow-up.
Overweight (child)
BMI ≥85th%tile for age and sex.
Measured: 2-year follow-up.
Obesity (child)
BMI ≥95th%tile for age and sex.
Measured: 2-year follow-up.
Anthropometry (child)
Abdominal circumference; age- and sex-adjusted per WHO z-scores for arm circumference.
Measured: 2-year follow-up.
Adiposity (child)
Triceps/subscapular skinfold thickness > 90th%tile for age and sex; individual and sum of measures.
Measured: 2-year follow-up.
Treatment Satisfaction Questionnaire for Medication (TSQM)
The TSQM (version 1.4) comprises 14 items across four domains focusing on effectiveness (three items), side effects (five items), convenience (three items), and global satisfaction (three items) of the medication over the previous 2-3 weeks. With the exception of item 4 (presence of side effects; yes or no), all items have five or seven responses, scored from one (least satisfied) to five or seven (most satisfied). Item scores are summed to give four domain scores, which are in turn transformed to a scale of 0-100. Item 4 was not included for scoring.
Measured: 6-weeks postpartum.
Questionnaire on Acceptability of Treatment
A set of 5 questions developed in the Rowan et al. RCT assessing patient adherence, preferences, and experiences with metformin versus insulin for GDM (Rowan et al., NEJM, 2008).
Measured: 6-weeks postpartum.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted6 Jun 2024
- Study start1 Aug 2024
- Primary completionDec 2029 (estimated)
- Study completionDec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for Gestational Diabetes MellitusStudies of the same condition, open and under way.
- More trials run by Ohio State UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 1,572 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ohio State University
- Sponsor type
- University, hospital or other
- Collaborators
- Patient-Centered Outcomes Research Institute, The George Washington University Biostatistics Center
- Responsible party
- Principal investigator, Kartik K Venkatesh, Ohio State University
- Investigators
- Kartik Venkatesh, MD, PhD, Principal investigator, Ohio State University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06445946
- Sponsor's protocol ID
- 2024H0193
- Acronym
- DECIDE
- Status last verified
- Oct 2026
- First submitted
- 21 May 2024
- Last updated
- 7 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
- Individual data sharing
- Yes: PCORI guidelines for data sharing will be followed, including the release of the Analyzable Data Set. This is the final cleaned and locked data set that contains all the data used in conducting the analyses reported in the PCORI Final Research Report and is de-identified in accordance with the HIPAA Privacy Rule.
Publications
Venkatesh KK, Chiang CW, Castillo WC, Battarbee AN, Donneyong M, Harper LM, Costantine M, Saade G, Werner EF, Boggess KA, Landon MB. Changing patterns in medication prescription for gestational diabetes during a time of guideline change in the USA: a cross-sectional study. BJOG. 2022 Feb;129(3):473-483. doi: 10.1111/1471-0528.16960. Epub 2021 Nov 8.
PubMed 34605130Venkatesh KK, Wu J, Trinh A, Cross S, Rice D, Powe CE, Brindle S, Andreatta S, Bartholomew A, MacPherson C, Costantine MM, Saade G, McAlearney AS, Grobman WA, Landon MB. Patient Priorities, Decisional Comfort, and Satisfaction with Metformin versus Insulin for the Treatment of Gestational Diabetes Mellitus. Am J Perinatol. 2024 May;41(S 01):e3170-e3182. doi: 10.1055/s-0043-1777334. Epub 2023 Dec 4.
PubMed 38049101Venkatesh KK, Lynch CD, Powe CE, Costantine MM, Thung SF, Gabbe SG, Grobman WA, Landon MB. Risk of Adverse Pregnancy Outcomes Among Pregnant Individuals With Gestational Diabetes by Race and Ethnicity in the United States, 2014-2020. JAMA. 2022 Apr 12;327(14):1356-1367. doi: 10.1001/jama.2022.3189.
PubMed 35412565Venkatesh KK, MacPherson C, Clifton RG, Powe CE, Bartholomew A, Gregory D, Trinh A, McAlearney AS, Fiechtner LG, Catalano P, Rice D, Cross S, Kutay H, Gabbe S, Grobman WA, Costantine MM, Battarbee AN, Boggess K, Katukuri V, Eichelberger K, Esakoff T, Feghali MN, Harper L, Kaimal A, Kole-White M, Mendez-Figueroa H, Mlynarczyk M, Sciscione A, Shook L, Sobhani NC, Stamilio DM, Werner E, Wiegand S, Zera CA, Zork NM, Saade G, Landon MB. Comparative effectiveness trial of metformin versus insulin for the treatment of gestational diabetes in the USA: clinical trial protocol for the multicentre DECIDE study. BMJ Open. 2024 Sep 24;14(9):e091176. doi: 10.1136/bmjopen-2024-091176.
PubMed 39317491